Stroke Prevention in Atrial Fibrillation


Despite the evidence-based guidelines for the management of atrial fibrillation (AF), serious gaps continue to exist between clinical knowledge and practice, leaving patients at risk for disabling strokes. It is estimated that up to 67% of AF-related strokes are preventable. The significant increase in mortality and functional impairment is even more alarming, compared to non-AF strokes.


Updated AF treatment guidelines recommend new oral anticoagulants (NOACs) over warfarin for stroke prevention except, in patients with moderate to severe mitral stenosis or a mechanical heart valve. Based on some recent trials, NOACs were superior to warfarin for the prevention of the composite of stroke and systemic embolism in patients with AF and an additional risk factor for stroke. Reversal agents are now also available for NOACs in patients for severe bleeding or emergency procedures.


With the increased utilization of NOACs, it is critical for the clinician to understand the clinical and practical usage of these agents in diverse patient populations and clinical situations.

Close X
Other videos you might like

Recent Videos

Video Series

EHRA 2024: Late-Breaking Science Video Collection

Laurent Fiorina,

Video Series

Rhythm Interventions Online 2023 - On Demand

Richard Schilling, KR Julian Chun, Vivek Reddy, et al


CardioNerds @AHA23: The ARTESiA Trial

Naima Maqsood, Jeff Healey,

Watch time: 11m 15s


ESC 23: The NOAH-AFNET 6 Trial

Paulus Kirchhof,

Watch time: 3m 42s

Video Series

ESC 23: Hot Line & Late-breaking Science Video Collection

Yugo Yamashita,


RIO 2022 – Six-month Case Retrospectives: In Full

Richard Schilling, KR Julian Chun, Devi Nair, et al

Watch time: 50m 43s